The global market for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) was estimated to be worth US$ 1133.8 million in 2023 and is forecast to a readjusted size of US$ 1410.3 million by 2030 with a CAGR of 3.1% during the forecast period 2024-2030

Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) - Market

Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by region & country, by Type, and by Application.

The Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eptacog Alfa (Recombinant Human Coagulation Factor VIIa).

Market Segmentation

Scope of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) - Market Report

Report Metric	Details
Report Name	Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) - Market
Forecasted market size in 2030	US$ 1410.3 million
CAGR	3.1%
Forecasted years	2024 - 2030
Segment by Type:	60 KIU 50 KIU
Segment by Application	Bleeding Surgery Assisted Glanzmann Plateletasthenia Hemophilia B Hemophilia A Head Trauma Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	BMS, Generium, Novo Nordisk, Shire (Baxter), Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, BPL, Hualan Bio, RAAS, Suzhou Alphamab
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) - Market size in 2030?

Ans: The Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) - Market size in 2030 will be US$ 1410.3 million.

Who are the main players in the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) - Market report?

Ans: The main players in the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) - Market are BMS, Generium, Novo Nordisk, Shire (Baxter), Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, BPL, Hualan Bio, RAAS, Suzhou Alphamab

What are the Application segmentation covered in the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) - Market report?

Ans: The Applications covered in the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) - Market report are Bleeding, Surgery Assisted, Glanzmann Plateletasthenia, Hemophilia B, Hemophilia A, Head Trauma, Others

What are the Type segmentation covered in the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) - Market report?

Ans: The Types covered in the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) - Market report are 60 KIU, 50 KIU

1 Market Overview

1.1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Introduction

1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size Forecast

1.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value (2019-2030)

1.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume (2019-2030)

1.2.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Price (2019-2030)

1.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Trends & Drivers

1.3.1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Industry Trends

1.3.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Drivers & Opportunity

1.3.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Challenges

1.3.4 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Players Revenue Ranking (2023)

2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Company (2019-2024)

2.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Players Sales Volume Ranking (2023)

2.4 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Company Players (2019-2024)

2.5 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Average Price by Company (2019-2024)

2.6 Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)

2.9 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Competitive Analysis

2.9.1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 60 KIU

3.1.2 50 KIU

3.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type

3.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, by Type (2019-2030)

3.2.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, by Type (%) (2019-2030)

3.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Type

3.3.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume, by Type (2019-2030)

3.3.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume, by Type (%) (2019-2030)

3.4 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Bleeding

4.1.2 Surgery Assisted

4.1.3 Glanzmann Plateletasthenia

4.1.4 Hemophilia B

4.1.5 Hemophilia A

4.1.6 Head Trauma

4.1.7 Others

4.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application

4.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, by Application (2019-2030)

4.2.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, by Application (%) (2019-2030)

4.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Application

4.3.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume, by Application (2019-2030)

4.3.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume, by Application (%) (2019-2030)

4.4 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Region

5.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Region (2019-2024)

5.1.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Region (2025-2030)

5.1.4 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Region (%), (2019-2030)

5.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Region

5.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Region (2019-2024)

5.2.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Region (2025-2030)

5.2.4 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Region (%), (2019-2030)

5.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

5.4.2 North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

5.5.2 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

5.6.2 Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

5.7.2 South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

5.8.2 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value

6.2.1 Key Countries/Regions Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

6.2.2 Key Countries/Regions Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

6.3.2 United States Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

6.4.2 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

6.5.2 China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

6.5.3 China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

6.6.2 Japan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

6.7.2 South Korea Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

6.8.2 Southeast Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019-2030

6.9.2 India Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

6.9.3 India Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 BMS

7.1.1 BMS Company Information

7.1.2 BMS Introduction and Business Overview

7.1.3 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.1.4 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.1.5 BMS Recent Development

7.2 Generium

7.2.1 Generium Company Information

7.2.2 Generium Introduction and Business Overview

7.2.3 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.2.4 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.2.5 Generium Recent Development

7.3 Novo Nordisk

7.3.1 Novo Nordisk Company Information

7.3.2 Novo Nordisk Introduction and Business Overview

7.3.3 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.3.5 Novo Nordisk Recent Development

7.4 Shire (Baxter)

7.4.1 Shire (Baxter) Company Information

7.4.2 Shire (Baxter) Introduction and Business Overview

7.4.3 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.4.5 Shire (Baxter) Recent Development

7.5 Bayer

7.5.1 Bayer Company Information

7.5.2 Bayer Introduction and Business Overview

7.5.3 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.5.5 Bayer Recent Development

7.6 CSL

7.6.1 CSL Company Information

7.6.2 CSL Introduction and Business Overview

7.6.3 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.6.4 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.6.5 CSL Recent Development

7.7 Pfizer

7.7.1 Pfizer Company Information

7.7.2 Pfizer Introduction and Business Overview

7.7.3 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.7.5 Pfizer Recent Development

7.8 Grifols

7.8.1 Grifols Company Information

7.8.2 Grifols Introduction and Business Overview

7.8.3 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.8.5 Grifols Recent Development

7.9 Biogen

7.9.1 Biogen Company Information

7.9.2 Biogen Introduction and Business Overview

7.9.3 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.9.4 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.9.5 Biogen Recent Development

7.10 Octapharma

7.10.1 Octapharma Company Information

7.10.2 Octapharma Introduction and Business Overview

7.10.3 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.10.4 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.10.5 Octapharma Recent Development

7.11 NovoNordisk

7.11.1 NovoNordisk Company Information

7.11.2 NovoNordisk Introduction and Business Overview

7.11.3 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.11.4 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.11.5 NovoNordisk Recent Development

7.12 Greencross

7.12.1 Greencross Company Information

7.12.2 Greencross Introduction and Business Overview

7.12.3 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.12.4 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.12.5 Greencross Recent Development

7.13 Kedrion

7.13.1 Kedrion Company Information

7.13.2 Kedrion Introduction and Business Overview

7.13.3 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.13.4 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.13.5 Kedrion Recent Development

7.14 BPL

7.14.1 BPL Company Information

7.14.2 BPL Introduction and Business Overview

7.14.3 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.14.4 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.14.5 BPL Recent Development

7.15 Hualan Bio

7.15.1 Hualan Bio Company Information

7.15.2 Hualan Bio Introduction and Business Overview

7.15.3 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.15.4 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.15.5 Hualan Bio Recent Development

7.16 RAAS

7.16.1 RAAS Company Information

7.16.2 RAAS Introduction and Business Overview

7.16.3 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.16.4 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.16.5 RAAS Recent Development

7.17 Suzhou Alphamab

7.17.1 Suzhou Alphamab Company Information

7.17.2 Suzhou Alphamab Introduction and Business Overview

7.17.3 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2019-2024)

7.17.4 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

7.17.5 Suzhou Alphamab Recent Development

8 Industry Chain Analysis

8.1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Industrial Chain

8.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Model

8.5.2 Sales Channel

8.5.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Trends

Table 2. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Drivers & Opportunity

Table 3. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Challenges

Table 4. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Restraints

Table 5. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Company (2019-2024)

Table 7. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)

Table 13. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Region (2019-2024) & (%)

Table 44. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Region (2025-2030) & (%)

Table 45. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Region (2019-2024) & (%)

Table 49. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Region (2025-2030) & (%)

Table 50. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume, (2025-2030) & (K Units)

Table 57. BMS Company Information

Table 58. BMS Introduction and Business Overview

Table 59. BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 61. BMS Recent Development

Table 62. Generium Company Information

Table 63. Generium Introduction and Business Overview

Table 64. Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 66. Generium Recent Development

Table 67. Novo Nordisk Company Information

Table 68. Novo Nordisk Introduction and Business Overview

Table 69. Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 71. Novo Nordisk Recent Development

Table 72. Shire (Baxter) Company Information

Table 73. Shire (Baxter) Introduction and Business Overview

Table 74. Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 76. Shire (Baxter) Recent Development

Table 77. Bayer Company Information

Table 78. Bayer Introduction and Business Overview

Table 79. Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 81. Bayer Recent Development

Table 82. CSL Company Information

Table 83. CSL Introduction and Business Overview

Table 84. CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 86. CSL Recent Development

Table 87. Pfizer Company Information

Table 88. Pfizer Introduction and Business Overview

Table 89. Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 91. Pfizer Recent Development

Table 92. Grifols Company Information

Table 93. Grifols Introduction and Business Overview

Table 94. Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 96. Grifols Recent Development

Table 97. Biogen Company Information

Table 98. Biogen Introduction and Business Overview

Table 99. Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 100. Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 101. Biogen Recent Development

Table 102. Octapharma Company Information

Table 103. Octapharma Introduction and Business Overview

Table 104. Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 105. Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 106. Octapharma Recent Development

Table 107. NovoNordisk Company Information

Table 108. NovoNordisk Introduction and Business Overview

Table 109. NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 110. NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 111. NovoNordisk Recent Development

Table 112. Greencross Company Information

Table 113. Greencross Introduction and Business Overview

Table 114. Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 115. Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 116. Greencross Recent Development

Table 117. Kedrion Company Information

Table 118. Kedrion Introduction and Business Overview

Table 119. Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 120. Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 121. Kedrion Recent Development

Table 122. BPL Company Information

Table 123. BPL Introduction and Business Overview

Table 124. BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 125. BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 126. BPL Recent Development

Table 127. Hualan Bio Company Information

Table 128. Hualan Bio Introduction and Business Overview

Table 129. Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 130. Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 131. Hualan Bio Recent Development

Table 132. RAAS Company Information

Table 133. RAAS Introduction and Business Overview

Table 134. RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 135. RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 136. RAAS Recent Development

Table 137. Suzhou Alphamab Company Information

Table 138. Suzhou Alphamab Introduction and Business Overview

Table 139. Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 140. Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings

Table 141. Suzhou Alphamab Recent Development

Table 142. Key Raw Materials Lists

Table 143. Raw Materials Key Suppliers Lists

Table 144. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Downstream Customers

Table 145. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Distributors List

Table 146. Research Programs/Design for This Report

Table 147. Key Data Information from Secondary Sources

Table 148. Key Data Information from Primary Sources

List of Figures

Figure 1. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Picture

Figure 2. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume (2019-2030) & (K Units)

Figure 5. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Price (2019-2030) & (US$/Unit)

Figure 6. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Report Years Considered

Figure 7. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue in 2023

Figure 10. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. 60 KIU Picture

Figure 12. 50 KIU Picture

Figure 13. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value Market Share by Type, 2023 & 2030

Figure 15. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 16. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume Market Share by Type, 2023 & 2030

Figure 17. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price by Type (2019-2030) & (US$/Unit)

Figure 18. Product Picture of Bleeding

Figure 19. Product Picture of Surgery Assisted

Figure 20. Product Picture of Glanzmann Plateletasthenia

Figure 21. Product Picture of Hemophilia B

Figure 22. Product Picture of Hemophilia A

Figure 23. Product Picture of Head Trauma

Figure 24. Product Picture of Others

Figure 25. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 26. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value Market Share by Application, 2023 & 2030

Figure 27. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 28. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume Market Share by Application, 2023 & 2030

Figure 29. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price by Application (2019-2030) & (US$/Unit)

Figure 30. North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value (2019-2030) & (US$ Million)

Figure 31. North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Country (%), 2023 VS 2030

Figure 32. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value (2019-2030) & (US$ Million)

Figure 33. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Country (%), 2023 VS 2030

Figure 34. Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value (2019-2030) & (US$ Million)

Figure 35. Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Country (%), 2023 VS 2030

Figure 36. South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value (2019-2030) & (US$ Million)

Figure 37. South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Country (%), 2023 VS 2030

Figure 38. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value (2019-2030) & (US$ Million)

Figure 39. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Country (%), 2023 VS 2030

Figure 40. Key Countries/Regions Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value (%), (2019-2030)

Figure 41. Key Countries/Regions Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Volume (%), (2019-2030)

Figure 42. United States Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, (2019-2030) & (US$ Million)

Figure 43. United States Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

Figure 44. United States Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application (%), 2023 VS 2030

Figure 45. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, (2019-2030) & (US$ Million)

Figure 46. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

Figure 47. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application (%), 2023 VS 2030

Figure 48. China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, (2019-2030) & (US$ Million)

Figure 49. China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

Figure 50. China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application (%), 2023 VS 2030

Figure 51. Japan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, (2019-2030) & (US$ Million)

Figure 52. Japan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

Figure 53. Japan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application (%), 2023 VS 2030

Figure 54. South Korea Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, (2019-2030) & (US$ Million)

Figure 55. South Korea Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

Figure 56. South Korea Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application (%), 2023 VS 2030

Figure 57. Southeast Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, (2019-2030) & (US$ Million)

Figure 58. Southeast Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

Figure 59. Southeast Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application (%), 2023 VS 2030

Figure 60. India Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value, (2019-2030) & (US$ Million)

Figure 61. India Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Type (%), 2023 VS 2030

Figure 62. India Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Value by Application (%), 2023 VS 2030

Figure 63. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Industrial Chain

Figure 64. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Cost Structure

Figure 65. Channels of Distribution (Direct Sales, and Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions